Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 6Thoracic 4Other solid neoplasm 2Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 4

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × vadimezan × Thoracic × Clear all
NCT00662597 2020-12-24

ATRACT-1

Novartis

Phase 3 Terminated
1,285 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00738387 2020-12-24

ATTRACT-2

Novartis

Phase 3 Terminated
900 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00674102 2020-12-09

An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)

Novartis

Phase 1 Completed
15 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00832494 2009-01-30

Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

Antisoma Research

Phase 1/2 Completed
105 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡